Analysts Expect Breakeven For Beijing Luzhu Biotechnology Co., Ltd. (HKG:2480) Before Long

Beijing Luzhu Biotechnology Co., Ltd. (HKG:2480) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Beijing Luzhu Biotechnology Co., Ltd., a biotechnology company, focuses on the research and development, production, and sale of human vaccines and therapeutic biologics to prevent and control infectious diseases, and treat cancer and autoimmune diseases in Mainland China. The HK$4.8b market-cap company’s loss lessened since it announced a CN¥168m loss in the full financial year, compared to the latest trailing-twelve-month loss of CN¥136m, as it approaches breakeven. The most pressing concern for investors is Beijing Luzhu Biotechnology's path to profitability – when will it breakeven? In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable.

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

According to the 3 industry analysts covering Beijing Luzhu Biotechnology, the consensus is that breakeven is near. They anticipate the company to incur a final loss in 2026, before generating positive profits of CN¥90m in 2027. The company is therefore projected to breakeven around 2 years from today. What rate will the company have to grow year-on-year in order to breakeven on this date? Using a line of best fit, we calculated an average annual growth rate of 66%, which is extremely buoyant. If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict.

Underlying developments driving Beijing Luzhu Biotechnology's growth isn’t the focus of this broad overview, however, take into account that typically biotechs, depending on the stage of product development, have irregular periods of cash flow. This means, large upcoming growth rates are not abnormal as the company is beginning to reap the benefits of earlier investments.

See our latest analysis for Beijing Luzhu Biotechnology

One thing we’d like to point out is that The company has managed its capital prudently, with debt making up 28% of equity. This means that it has predominantly funded its operations from equity capital, and its low debt obligation reduces the risk around investing in the loss-making company.

Next Steps:

There are key fundamentals of Beijing Luzhu Biotechnology which are not covered in this article, but we must stress again that this is merely a basic overview. For a more comprehensive look at Beijing Luzhu Biotechnology, take a look at Beijing Luzhu Biotechnology's company page on Simply Wall St. We've also put together a list of essential factors you should further examine:

1. Valuation: What is Beijing Luzhu Biotechnology worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Beijing Luzhu Biotechnology is currently mispriced by the market.
2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Beijing Luzhu Biotechnology’s board and the CEO’s background.
3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.